Six pilot pharmaceutical enterprises enjoy monopoly advantages

While the industry is looking forward to the expansion of pilot enterprises of traditional Chinese medicine formula granules, a recent notice from the State Food and Drug Administration suddenly tightened the threshold This has temporarily stopped the pharmaceutical enterprises that intend to apply for the formulation granules of traditional Chinese medicine, and enabled six state-level pilot enterprises such as China Resources Sanjiu, Shanghai Jiahua and HongRi Pharmaceutical Co., Ltd to continue to maintain their monopoly advantages On June 28, the State Food and Drug Administration issued a notice to strictly regulate the processing of Chinese herbal pieces and the pilot research and management of Chinese herbal formula granules The notice stressed that the traditional Chinese medicine formula granules are still in the pilot research, and the State Food and Drug Administration will work with relevant departments to promote the pilot research of traditional Chinese medicine formula granules, find problems, summarize experience, and timely issue relevant regulations Before that, the provincial food and drug administration shall not approve the production of traditional Chinese medicine formula granules in any name It is understood that since the implementation of the Interim Provisions on the administration of granules of traditional Chinese medicine in July 2001, Jiangyin Tianjiang pharmaceutical, kangrentang, China Resources Sanjiu, Guangdong Yifang, Peili (Nanning) Pharmaceutical Co., Ltd and Sichuan green pharmaceutical science and Technology Development Co., Ltd have successively obtained the national pilot production enterprise qualification The business expansion of traditional Chinese medicine formula granules has gradually become a new profit growth point for traditional Chinese medicine enterprises According to the data, HongRi pharmaceutical industry achieved an operating revenue of 1.229 billion yuan in 2012, including 498 million yuan of traditional Chinese medicine formula granules, a year-on-year increase of 85.69% and a gross profit rate of 74.39% According to the 2012 annual report of Shanghai Jiahua, last year, Jiangyin Tianjiang had an operating revenue of 1.892 billion yuan, an operating profit of 484 million yuan, and a net profit of 411 million yuan The investment income contributed by the participating companies accounted for 16.54% of the net profit of the listed companies, and it became the only enterprise with an investment income of more than 10% of that of Shanghai Jiahua's participating companies What is the industry prospect of traditional Chinese medicine granule business? The data shows that the traditional Chinese medicine formula granules, as the substitute of traditional Chinese medicine pieces, are in the golden growth period of rapid development The total income of formula granule industry increased from 230 million yuan in 2006 to about 3.2 billion yuan in 2012, with an average compound growth rate of more than 50% Yesterday, reporters learned from China Resources Sanjiu and HongRi pharmaceutical that the company is currently interpreting and studying the policy "The development plan of TCM formula granules will be disclosed in detail in the semi annual report," HongRi pharmaceutical said